


AMENDMENTS TO THE CLAIMS


1-2. (Canceled).

3. (Previously presented) A compound represented by the formula:



[wherein R^1 is a group represented by the formula $-G^{1z}-R^{1z}$ (wherein G^{1z} is a single bond, oxygen or sulfur, and R^{1z} is methyl or ethyl) or methoxymethyl;

R^5 and R^6 are each independently hydrogen, *t*-butoxycarbonyl or a group represented by the formula $-X^{6b}-X^{7b}$ (wherein X^{6b} is methylene and X^{7b} is C_{1-6} alkyl, C_{3-8} cycloalkyl, tetrahydropyran-yl or tetrahydrofuran-yl); and wherein R^{40} and R^{42} are each independently C_{1-6} alkoxy, and R^{41} is a group represented by the formula:




(wherein R^{44} and R^{45} are each independently hydrogen, methyl or ethyl; and R^{43} is C_{1-6} alkyl optionally substituted with 1 to 3 substituents selected from Substituent Group B below,

wherein Substituent Group B is the group consisting of fluorine atom, chlorine atom, bromine atom, cyano, C_{1-6} alkoxy, pyrrolidinyl, piperazinyl, piperidyl, morpholinyl, C_{3-8} cycloalkyl, tetrahydropyran-yl and tetrahydrofuran-yl),

a salt thereof or a hydrate of the foregoing.

4. (Original) A compound represented by the formula:



[wherein R^{5t} and R^{6t} are each independently cyclopropylmethyl, (4-tetrahydropyranyl)methyl, (3-tetrahydrofuranyl)methyl or (2-tetrahydrofuranyl)methyl;

R^{1t} is methoxy, methylthio, methyl, ethyl or methoxymethyl; and

R^{43t} is C₁₋₆ alkyl],

a salt thereof or a hydrate of the foregoing.

5. (Original) A compound according to claim 4, a salt thereof or a hydrate of the foregoing, wherein R^{43t} is methyl.

6. (Original) A compound according to claim 4, a salt thereof or a hydrate of the foregoing, wherein R^{1t} is methoxy, methylthio or ethyl.

7. (Original) A compound according to claim 4, a salt thereof or a hydrate of the foregoing, wherein R^{5t} is cyclopropylmethyl or (4-tetrahydropyranyl)methyl.

8. (Original) A compound according to claim 4, a salt thereof or a hydrate of the foregoing, wherein R^{5t} is (4-tetrahydropyranyl)methyl.

9. (Original) A compound according to claim 4, a salt thereof or a hydrate of the foregoing, wherein R^{5t} is (4-tetrahydropyranyl)methyl, and R^{6t} is cyclopropylmethyl.

10. (Previously presented) A compound according to claim 3, a salt thereof or a hydrate of the foregoing, wherein the compound is *N*-cyclopropylmethyl-*N*-7-[2,6-dimethoxy-4-(methoxymethyl)phenyl]-2-ethylpyrazolo[1,5-*a*]pyridin-3-yl-*N*-tetrahydro-2*H*-4-pyranylmethylamine, *N*-cyclopropylmethyl-*N*-7-[4-(ethoxymethyl)-2,6-dimethoxyphenyl]-2-ethylpyrazolo[1,5-*a*]pyridin-3-yl-*N*-tetrahydro-2*H*-4-pyranylmethylamine or *N*-cyclopropylmethyl-*N*-[7-[2,6-dimethoxy-4-(methoxymethyl)phenyl]-2-(methylsulfanyl)pyrazolo[1,5-*a*]pyridin-3-yl]-*N*-tetrahydro-2*H*-4-pyranylmethylamine.

11. (Previously presented) A compound according to claim 3, a salt thereof or a hydrate of the foregoing, wherein the compound is *N*-cyclopropylmethyl-*N*-7-[2,6-dimethoxy-4-(methoxymethyl)phenyl]-2-ethylpyrazolo[1,5-*a*]pyridin-3-yl-*N*-tetrahydro-2*H*-4-pyranylmethylamine.

12-14. (Canceled).

15. (Previously presented) A corticotropin-releasing factor (CRF) receptor antagonist comprising a compound according to claim 3 or a salt thereof and a pharmaceutically acceptable carrier.

16-29. (Canceled).

30. (Previously presented) A therapeutic method for treating at least one disease selected from the group consisting of depression, general anxiety disorder and anxiety, comprising administration of an effective amount of a compound according to claim 3 or a salt thereof for treating said disease.